Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.

Leukemia - 1 Jun 2023

Rausch Christian, Rothenberg-Thurley Maja, Dufour Annika, Schneider Stephanie, Gittinger Hanna, Sauerland Cristina, Görlich Dennis, Krug Utz, Berdel Wolfgang E, Woermann Bernhard J, Hiddemann Wolfgang, Braess Jan, von Bergwelt-Baildon Michael, Spiekermann Karsten, Herold Tobias, Metzeler Klaus H

Abstract excerpt

The revised 2022 European LeukemiaNet (ELN) AML risk stratification system requires validation in large, homogeneously treated cohorts. We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18-86 years) who received cytarabine-based induction chemotherapy between 1999 and 2012 and compared ELN-2022 to the previous ELN-2017 risk classification. Key findings were validated in a cohort of 1160...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Risk Assessment

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37041198
DOI: 10.1038/s41375-023-01884-2
PMCID: PMC10244159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.PMID 37041198Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.Semantic proximity Read ↗

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.Semantic proximity Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.Semantic proximity Read ↗

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.